← Back to all trials
Completed
NCT07664007
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.
Conditions: Hepatocellular Carcinoma
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 18
Sponsor: Instituto de Investigación Sanitaria Aragón
Location: Hospital Clínico Universitario Lozano Blesa. IIS Aragón Zaragoza Zaragoza
Summary
Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.
Eligibility Criteria
Inclusion Criteria:
* Participants diagnosed with unresectable HCC, candidates for systemic treatment with Sorafenib or similar agents.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Life expectancy \> 8 weeks.
* Not eligible for curative treatment (surgical resection/ablative therapy/liver transplantation).
* Not having a history of previous or concomitant malignancy except when a disease-free interval \> 5 years had been documented.
* Not receiving any other systemic antitumor agents (docetaxel, doxorubicin, irinotecan).
Exclusion Criteria:
* Allergy to omega-3 acid or fish-derived products.
* Psychological or medical conditions that can interfere with study participation or the ability to provide informed consent.
* Drug abuse (except for alcohol).
* Any experimental therapy within 30 days prior to study entry.
* Recurrent epistaxis
Source: ClinicalTrials.gov (NCT07664007). StuddyBuddy aggregates publicly available trial information.
